Actinium Pharmaceuticals (ATNM) Posts Earnings Results, Beats Estimates By $0.02 EPS

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.04) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.06) by $0.02, Bloomberg Earnings reports.

Actinium Pharmaceuticals opened at $0.61 on Friday, according to MarketBeat Ratings. Actinium Pharmaceuticals has a 12 month low of $0.33 and a 12 month high of $0.85.

A number of research analysts have recently weighed in on the company. Zacks Investment Research upgraded Actinium Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 price objective for the company in a research report on Tuesday, July 24th. B. Riley raised their price objective on Actinium Pharmaceuticals from $2.75 to $3.00 and gave the company a “buy” rating in a research report on Thursday, July 12th. Finally, Maxim Group reiterated a “buy” rating on shares of Actinium Pharmaceuticals in a research report on Thursday, June 14th. Five equities research analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and an average price target of $3.75.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.

See Also: New Google Finance Tool and Screening Stocks

Earnings History for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply